RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
1-Year Return
18.15%
This Quarter Return
+42.01%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$6.4B
AUM Growth
+$1.32B
(+26%)
Cap. Flow
+$71M
Cap. Flow
% of AUM
1.11%
Top 10 Holdings %
Top 10 Hldgs %
60.92%
Holding
71
New
5
Increased
8
Reduced
9
Closed
9
Top Buys
| 1 |
IMGN
Immunogen Inc
IMGN
|
$309M |
| 2 |
MacroGenics
MGNX
|
$35.7M |
| 3 |
C4 Therapeutics
CCCC
|
$27.6M |
| 4 |
UroGen Pharma
URGN
|
$24M |
| 5 |
Structure Therapeutics
GPCR
|
$19.8M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$77.1M |
| 2 |
Cogent Biosciences
COGT
|
$62.6M |
| 3 |
Soleno Therapeutics
SLNO
|
$36.6M |
| 4 |
Avidity Biosciences
RNA
|
$35.9M |
| 5 |
CureVac
CVAC
|
$33.1M |
Sector Composition
| 1 | Healthcare | 99.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cytek Biosciences
CTKB
$501M
| $62.1M | 0.97% |
6,809,404
| – | – |
|
27
Acumen Pharmaceuticals
ABOS
$82.4M
| $57.3M | 0.9% |
14,932,063
| – | – |
|
28
PepGen
PEPG
$40.7M
| $55.3M | 0.86% |
8,131,952
| – | – |
|
29
Apogee Therapeutics
APGE
$2.2B
| $55.3M | 0.86% |
1,977,901
| – | – |
|
30
ARS Pharmaceuticals
SPRY
$1.05B
| $51.8M | 0.81% |
9,459,678
| – | – |
|
31
Nkarta
NKTX
$145M
| $51.5M | 0.8% |
7,805,129
| – | – |
|
32
Vor Biopharma
VOR
$243M
| $51.2M | 0.8% |
22,748,880
| – | – |
|
|
ITOS
33
DELISTED
iTeos Therapeutics
ITOS
| $48.4M | 0.76% |
4,417,259
| – | – |
|
34
Madrigal Pharmaceuticals
MDGL
$9.56B
| $47.3M | 0.74% |
204,500
| – | – |
|
|
35
UroGen Pharma
URGN
$895M
| $46.3M | 0.72% |
3,083,430
+1,599,733
| +108% | +$24M |
|
|
36
MacroGenics
MGNX
$119M
| $39M | 0.61% |
4,053,077
+3,711,077
| +1,085% | +$35.7M |
|
|
CLYM
37
Climb Bio, Inc. Common Stock
CLYM
$160M
| $35.5M | 0.55% |
13,150,849
| – | – |
|
38
Taysha Gene Therapies
TSHA
$865M
| $32.7M | 0.51% |
18,472,503
| – | – |
|
39
GH Research
GHRS
$871M
| $32.4M | 0.51% |
5,587,333
| – | – |
|
40
Enliven Therapeutics
ELVN
$1.2B
| $29.4M | 0.46% |
2,122,465
| – | – |
|
|
41
C4 Therapeutics
CCCC
$185M
| $27.6M | 0.43% |
+4,878,000
| New | +$27.6M |
|
42
Mineralys Therapeutics
MLYS
$2.03B
| $27.3M | 0.43% |
3,178,476
| – | – |
|
43
Werewolf Therapeutics
HOWL
$60.8M
| $23.7M | 0.37% |
6,144,881
| – | – |
|
44
Acrivon Therapeutics
ACRV
$41.8M
| $23.7M | 0.37% |
4,810,508
| – | – |
|
45
Pliant Therapeutics
PLRX
$98.2M
| $23.2M | 0.36% |
1,281,000
-481,000
| -27% | -$8.71M |
|
|
THRD
46
DELISTED
Third Harmonic Bio
THRD
| $22.3M | 0.35% |
2,033,056
+1,071,193
| +111% | +$11.8M |
|
|
47
Avidity Biosciences
RNA
$6.15B
| $22.2M | 0.35% |
2,454,533
-3,962,465
| -62% | -$35.9M |
|
48
Solid Biosciences
SLDB
$428M
| $21M | 0.33% |
3,426,286
| – | – |
|
|
49
Structure Therapeutics
GPCR
$1.07B
| $19.8M | 0.31% |
+486,832
| New | +$19.8M |
|
50
Tenaya Therapeutics
TNYA
$191M
| $17.8M | 0.28% |
5,507,347
-1,211,136
| -18% | -$3.92M |
|